"We are excited to be working with Diagnoplex on developing their technology for the non-invasive detection of colon cancer. Colon cancer is one of the leading causes of death and early detection makes a huge difference in patient survival. Since compliance with guidelines for screening with colonoscopy is poor, too many cases are detected too late. The need for non-invasive screening is tremendous," said Anja KÃ¶nig.
"Diagnoplex is targeting a very exciting market opportunity for molecular diagnostics. With the rise of personalized medicine, this is one of the healthcare areas with vast market potential that is currently underserved. We believe that Diagnoplex will be a leader in this important field," said Thomas Goebel.
"We are excited to welcome a high quality group of investors and look forward to working with this outstanding syndicate to bring powerful new cancer screening approaches to bear on the early detection of cancer," said Stavros Therianos, Ph.D., chief executive officer and founder of Diagnoplex.
About Novartis Venture Fund
Novartis Venture Fund, established in 1996, has currently over $650
million under management and is invested in more than 50 private companies.
The Novartis Venture Fund invests in companies which have the potential to
lead the next innovation wave in core therapeutic fields or explore new
business areas that will be critical to patient care. The NVF team of eight
investment professionals located in Basel,
Copyright©2008 PR Newswire.
All rights reserved